Expression of SLC25A48 in Chronic Obstructive Pulmonary Disease

Association Between SLC25A48 Expression and Chronic Obstructive Pulmonary Disease Progression

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07474220

Enrollment

180

Registered

2026-03-16

Start date

2026-06-29

Completion date

2026-12-31

Last updated

2026-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Keywords

Chronic obstructive pulmonary disease, Mitochondrial choline transport, SLC25A48, Inflammatory markers, Choline metabolism

Brief summary

This study aims to investigate the expression level of SLC25A48, a mitochondrial choline transporter, in peripheral blood mononuclear cells of patients with chronic obstructive pulmonary disease, and to analyze its correlation with inflammatory markers and choline metabolic byproducts.

Detailed description

Background: Chronic obstructive pulmonary disease is the third leading cause of death worldwide, characterized by airflow limitation, alveolar damage, and chronic systemic inflammation. These features are closely associated with malnutrition, muscle loss, and oxidative stress. Mitochondrial dysfunction plays a critical role in immune dysregulation, with peripheral blood mononuclear cells widely used in studies on inflammation and metabolism. Choline, essential for one-carbon metabolism and immune function, requires specific transporters to enter mitochondria. SLC25A48, a newly identified mitochondrial choline transporter, is linked to impaired choline uptake, elevated reactive oxygen species, and metabolic imbalance. However, its role in chronic obstructive pulmonary disease remains unclear. Study Design: This multicenter, prospective observational study Methods: The expression of SLC25A48 in peripheral blood mononuclear cells will be quantified and analyzed in relation to inflammatory markers and choline metabolism indicators. All participants will undergo pulmonary function testing, nutritional and quality of life assessments, and blood biochemistry. Peripheral blood mononuclear cells will be isolated using density gradient centrifugation, followed by protein extraction and quantification via Western blot and image-based analysis.

Interventions

None listed

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* pre-COPD or COPD stages I-IV as per the 2023 GOLD guidelines (case group) * healthy individuals without chronic diseases or major medical conditions

Exclusion criteria

* diagnosed with neuromuscular diseases * experienced respiratory disease exacerbation requiring emergency care or hospitalization in the past three months * assessed by a physician to have severe malnutrition or a significantly low BMI * continuously taking folic acid supplements * willing to receive or have already received self-paid nutrition clinic services at this hospital

Design outcomes

Primary

Measure	Time frame	Description
expression of SLC25A48	one day	the expression level of SLC25A48 in mitochondria isolated from peripheral blood mononuclear cells

Countries

Taiwan

Contacts

CONTACTKe-Yun Chao, PhD

ck_qq@hotmail.com+886-905-301-879

PRINCIPAL_INVESTIGATORKe-Yun Chao, PhD

Fu Jen Catholic University

Outcome results